Last Updated: November 13, 2026

Details for Patent: 11,939,361

Name: Drug Patent Intelligence for US Patent 11939361
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which drugs does patent 11,939,361 protect, and when does it expire?

Patent 11,939,361 protects ICOTYDE and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: 11,939,361

Title:	Compositions of peptide inhibitors of Interleukin-23 receptor
Abstract:	The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
Inventor(s):	Giustino Di Pretoro, Dajun SUN, Gopal Rajan, Geraldine BROECKX, Nathalie MERTENS, Shu Li, Felix Lai, Mohammad MASJEDIZADEH, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
Assignee:	Janssen Pharmaceutica NV , Protagonist Therapeutics Inc
Application Number:	US17/531,538
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 11,939,361

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	ICOTYDE	icotrokinra hydrochloride	TABLET;ORAL	220149-001	Mar 17, 2026		RX	Yes	Yes	11,939,361	⤷ Start Trial	Y			TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WHO WEIGH AT LEAST 40 KG WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,939,361

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2021383828	⤷ Start Trial
Canada	3202226	⤷ Start Trial
Chile	2023001417	⤷ Start Trial
China	116669710	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.